Nonetheless, it seems rational to check, as a rule, the expression of CK19 by immunohistochemistry in all newly diagnosed breast carcinomas in order to decide whether the analysis of SLN should preferably be done using the OSNA assay or conventional procedures. This evidence concerns the gene KRT19 and breast carcinoma.